The overall objective of this research program is to determine the importance of various tumor cell subpopulations in predicting a tumor's response to single and combined modality therapies. Cell subpopulations will be derived from solid KHT, RIF-1 or EMT6/Ro tumors using centrifugal elutriation. Experiments are proposed to determine the proportion and cell cycle location of quiescent (Q) cells and to measure growth imbalance in these solid tumor models using acridine orange (AO) staining and flow cytometric (FCM) analysis. The location, with respect to cell cycle phase and proliferation state, of oxygen-deficient (hypoxic) tumor cells will be characterized using radiation cell survival curve analysis, combinations of centrifugal elutriation plus viable cell sorting (Hoechst 33342) and the identification of hypoxic cells through the use of labelled hypoxic cell sensitizers. In situ sensitivity differences of various tumor cell subpopulations (including hypoxic and quiescent cells) will also be determined. It is further an objective to assess which subpopulations are most affected by radiation, sensitizers and selected chemotherapeutic agents. Possible interactions of sensitizers, drugs and radiation in terms of their effects on the total tumor as well as specific subpopulations will be evaluated. These studies should allow the development of mechanisms of interactions for the different combined modality treatments. Experiments aimed at determining the response of tumors and their subpopulations to different fractionated dose regimen also will be performed. In particular the effects of fractionated therapies on cell cycle redistribution and quiescent cell recruitment will be measured. These investigations should produce information which will improve the understanding of the role played by various cell subpopulations in determining the overall response of tumors to therapy and which may guide the efforts for the most effective use of combinations of radiation, chemotherapeutic agents and sensitizers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA036858-02
Application #
3174436
Study Section
Radiation Study Section (RAD)
Project Start
1984-05-01
Project End
1987-04-30
Budget Start
1985-05-01
Budget End
1986-04-30
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
Schools of Medicine
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Salmon, Howard W; Siemann, Dietmar W (2004) Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiother Oncol 73:359-66
Mendenhall, W M; Amdur, R J; Siemann, D W et al. (2000) Altered fractionation in definitive irradiation of squamous cell carcinoma of the head and neck. Curr Opin Oncol 12:207-14
Siemann, D W; Hinchman, C A (1998) Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiother Oncol 47:215-20
Siemann, D W; Johansen, I M; Horsman, M R (1998) Radiobiological hypoxia in the KHT sarcoma: predictions using the Eppendorf histograph. Int J Radiat Oncol Biol Phys 40:1171-6
Li, L; Rojiani, A; Siemann, D W (1998) Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42:899-903
Keng, P C; Siemann, D W (1998) Measurement of proliferation activities in human tumor models: a comparison of flow cytometric methods. Radiat Oncol Investig 6:120-7
Warrington Jr, K H; Teschendorf, C; Cao, L et al. (1998) Developing VDEPT for DT-diaphorase (NQO1) using an AAV vector plasmid. Int J Radiat Oncol Biol Phys 42:909-12
Siemann, D W (1998) The tumor microenvironment: a double-edged sword. Int J Radiat Oncol Biol Phys 42:697-9
Richardson, M E; Siemann, D W (1997) Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance. Int J Radiat Oncol Biol Phys 39:789-95
Horsman, M R; Siemann, D W; Chaplin, D J et al. (1997) Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother Oncol 45:167-74

Showing the most recent 10 out of 34 publications